Health Trials

About this trial

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)

Eligibility criteria

Qualifiers

patients with advanced ovarian cancer or other cancers with expression of claudin6.

Life expectancy >12 weeks

Adequate heart,lung,liver,kidney function

Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay

Disqualifiers

Had accepted gene therapy before;

Tumor size more than 25cm;

Severe virus infection such as HBV,HCV,HIV,et al

Known HIV positivity

Trial design

Treatments tested in this trial

  • Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells

Treatment groups

200 Participants
are divided into 5 treatment groups

Locations

1
The Second Affiliated Hospital of Guangzhou Medical University GuangzhouGuangdong, China

Sponsors and collaborators

Second Affiliated Hospital of Guangzhou Medical University

Lead sponsor

Source ClinicalTrials.gov